Ras/Raf signalling and emerging pharmacotherapeutic targets.
about
Role of H-Ras/ERK signaling in carbon nanotube-induced neoplastic-like transformation of human mesothelial cellsAbsence of mutations in the coding sequence of the potential tumor suppressor 3pK in metastatic melanomaBeta adrenergic overstimulation impaired vascular contractility via actin-cytoskeleton disorganization in rabbit cerebral arteryExploring anti-bacterial compounds against intracellular LegionellaIdentification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK bindingSalmeterol attenuates the inflammatory response in asthma and decreases the pro-inflammatory cytokine secretion of dendritic cells.The structure of the MAPK scaffold, MP1, bound to its partner, p14. A complex with a critical role in endosomal map kinase signaling.Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies.Therapeutic vaccines for gastrointestinal cancers.Effect of Repeated Electroacupuncture Intervention on Hippocampal ERK and p38MAPK Signaling in Neuropathic Pain Rats.A large animal model to evaluate the effects of Hsp90 inhibitors for the treatment of lung adenocarcinoma.Targeting prostate cancer based on signal transduction and cell cycle pathways.In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors.A novel noncanonical signaling pathway for the μ-opioid receptor.A systems biology view of cancerAllosteric modulators of MEK1: drug design and discovery.Lys63-linked polyubiquitination of BRAF at lysine 578 is required for BRAF-mediated signaling.Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells.Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction.Injury-induced neurogenesis in Bax-deficient mice: evidence for regulation by voltage-gated potassium channels.Dissecting Cell-Fate Determination Through Integrated Mathematical Modeling of the ERK/MAPK Signaling Pathway.Determination of Structural Requirements of N-Substituted Tetrahydro-β-Carboline Imidazolium Salt Derivatives Using in Silico Approaches for Designing MEK-1 Inhibitors.The impact of the regulatory design on the response of epidermal growth factor receptor-mediated signal transduction towards oncogenic mutations.Immunohistochemical detection of Raf kinase inhibitor protein in normal cervical tissue and cervical cancer tissue.
P2860
Q23923553-0C4BC003-71A4-4AE1-A689-094A8BF0394EQ25255935-C5893786-0DB8-4E2D-B547-515CE4BDF6A4Q28482409-AD9E4A11-4631-4D03-911A-0FEEB08202B2Q28533449-D346B9CB-6FD8-49F7-844F-CACC5C69694CQ28648013-86E9D7F0-F5BC-4F42-B3BD-279B868D9AF0Q33577392-5A23332C-1614-4723-8E51-1AA1EDCF073BQ34305323-88448A26-FCD1-475E-AB43-DFDB37C5C4B6Q35020561-D6D0F2EF-F294-43A1-84FC-958CC09E7144Q35691248-68DF609F-23ED-4E0C-8EC1-A20A5A6AFBBBQ35804597-934C33A3-F9B7-4EFC-97BD-11B356322B7CQ36593621-1D7A2344-D79F-46C5-AC69-BD857812A3D6Q36995054-C83571F2-1B51-4A54-BF32-A6743BAC10A5Q37162216-AEC6DEE5-2692-46A6-8787-E689E696DA85Q37325629-1707A99C-F2AD-4DE0-A328-262E73574C63Q37434945-48C0AE6C-A78D-4C5E-B814-00C1A836F9EAQ38817910-4136CF7A-5F24-4E65-AAFD-BD38813BB0CAQ39116774-45FDB235-F53D-45E8-90E0-4C588A3F21DDQ40391830-5989F2B9-1456-47BD-BA40-08E6CB80DDB6Q44263078-896CA7C4-501D-48DC-BCD4-337191CB04D6Q48116744-B8316091-60D4-4F96-8EB6-2C77EE303943Q50538898-59F70B12-5981-44B2-9C8D-8A2FA2E506D6Q50936315-F902364C-8D81-4D72-86F8-5991EA74362AQ51904547-7331E0A8-0D35-4D72-A192-80B22EF5E832Q54581866-BAD6603A-BA9C-4D1F-B649-68C6BCA5FC53
P2860
Ras/Raf signalling and emerging pharmacotherapeutic targets.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Ras/Raf signalling and emerging pharmacotherapeutic targets.
@en
Ras/Raf signalling and emerging pharmacotherapeutic targets.
@nl
type
label
Ras/Raf signalling and emerging pharmacotherapeutic targets.
@en
Ras/Raf signalling and emerging pharmacotherapeutic targets.
@nl
prefLabel
Ras/Raf signalling and emerging pharmacotherapeutic targets.
@en
Ras/Raf signalling and emerging pharmacotherapeutic targets.
@nl
P2860
P356
P1476
Ras/Raf signalling and emerging pharmacotherapeutic targets.
@en
P2860
P304
P356
10.1517/14656566.3.6.709
P407
P50
P577
2002-06-01T00:00:00Z